Psoriasis

Patients with allergic diseases may have an increased risk for developing psoriasis, according to study results presented at the American Academy of Dermatology virtual meeting.

The gap between patient-reported outcomes and clinician-assessed endpoints in rheumatology is well documented. Patients generally care about pain, fatigue and the emotional toll immune-mediated diseases can take, while physicians are more likely to pay attention to interleukin activity or C-reactive protein levels.

Etanercept monotherapy or a combination of etanercept and methotrexate had better psoriasis outcomes than methotrexate alone, according to a poster presented at the American Academy of Dermatology virtual meeting.

For U.S. patients with moderate to severe psoriasis, the South may be the best region to live, with the Midwest as the least ideal region, based on health care use and costs, according to a study.

Patients treated with biologic therapy for inflammatory diseases may not have a higher risk for developing melanoma, a systematic review and meta-analysis found.

Despite the often-devastating impact of psoriasis on children, and a variety of unique issues distinguishing these patients from adults, there has, until recently, been a lack of guidelines that specifically cater to juveniles with the disease.

Among patients with psoriasis, poor mental health status correlated with dissatisfaction with physician care, according to a study.

Let’s start with what we currently know about COVID-19, an illness caused by severe acute respiratory syndrome coronavirus 2, also known as SARS-CoV-2. It is a single-stranded RNA virus transmitted primarily by respiratory droplets from coughs and sneezes.

A daily regimen of oral serlopitant was associated with a significant reduction in pruritus in a small cohort of patients with mild to moderate psoriasis, according to a study.

A dose reduction schedule of biologics did not show noninferiority to the standard of care based on Psoriasis Area and Severity Index; however, quality of life scores did show noninferiority, according to a clinical trial.